PATENT CLAIM ANALYSIS

Application Number: 15877436
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["424", "133100"]

Abstract:
The present invention relates to a pharmaceutical composition comprising PD-1 antagonist and an EGFR Inhibitor. The present combination can be administered independently or separately, in a quantity which is jointly therapeutically effective for the treatment of cancer. The invention also provides the use of such a combination for the manufacture of a medicament; the use of such a combination as a medicine; a kit of part comprising such a combination; and a method of treatment of such a combination.

Claim (Index 55):
An isolated antibody molecule capable of binding to a human Programmed Death-1 (PD-1) as described in  claim 41 , in combination with (R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1Hbenzo[d]imidazol-2-yl)-2-methylisonicotinamide, or a pharmaceutically acceptable salt thereof, for use in the treatment of NSCLC, colorectal cancer, triple negative breast cancer, or a cancer that has become resistant or refractory to PD-1 or PD-L1 therapy,\n optionally wherein the PD-1 or PD-L1 therapy is therapy with pembrolizumab, nivolumab, atezolizumab and MEDI4736.PD-1.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 86.0
- Lexical Diversity: 1.79167
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14604415', '15751140', '14881888', '15595618', '14610837']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7594490738612728
- 35 USC 102 Novelty (BERT): 0.5299869504683513
- Combined Prediction Score: 0.7365028615219806
- Mean Citation Score: 334.040494
- Max Citation Score: 353.73898
- Similarity Product: 253.38093694333912

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test